Ultra-long-term results of the Chiari pelvic osteotomy in hip dysplasia patients: a minimum of thirty-five years follow-up
International Orthopaedics · 2024
DOI: 10.1007/s00264-023-05912-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Orthopaedics, 2024. Verfasst von Catharina Chiari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Orthopaedics, Department of Orthopaedics and Trauma-Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austri…. Hauptthemen laut MEDLINE: Hip Dislocation, Hip Dislocation, Congenital, Osteoarthritis, Hip. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
Purpose
The Chiari pelvic osteotomy was the first surgical procedure to address hip dysplasia by changing the position of the acetabulum by medialization, thus creating a bony roof and improving biomechanical conditions. The aim of this retrospective cohort study was to report on the very long-term results of this technique.
Methods
Out of a consecutive series of 1536 hips, 504 in 405 patients were available for follow-up. The patients were assessed by physical and radiological examination. A Kaplan–Meier survival analysis with total hip arthroplasty as an endpoint was performed and stratified for age groups, pre-operative diagnosis, sex and osteoarthritis stage.
Results
The average follow-up was 36 ± 8.1 years (range, 35.2 to 54). The average pain level on the Visual Analogue Scale was 2.9 ± 2.6 (range 0 to 8.7). The average Harris Hip Score was 80.2 ± 17.4 (range 17.4 to 100). Correction of dysplasia was effective and remained stable over time. Osteoarthritis significantly increased over time with 53% Tönnis grade 3 at follow-up. The cumulative survivorship was 79.8% (95% confidence interval (CI), 76.1–83.2%) at 20 years, 57.1% (95% CI, 52.8–61.8%) at 30 years and 35% (95% CI, 30.3–40.3%) at 40 years. Young age, male sex and low osteoarthritis grade were positive prognostic factors.
Conclusions
Although the Chiari pelvic osteotomy is considered a salvage procedure nowadays, it achieved excellent long-term results even in indications, which would be treated differently today. Young patients without osteoarthritis had the best outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Orthopaedics, Department of Orthopaedics and Trauma-Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. catharina.chiari@meduniwien.ac.at.
- Division of Orthopaedics, Department of Orthopaedics and Trauma-Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
- Center for Medical Statistics, Informatics and Intelligent Systems, Institute of Outcomes Research, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.
- Radiology Center, Lazarettgasse 25, 1090, Vienna, Austria.
- Vienna Private Hospital, Pelikangasse 15, 1090, Vienna, Austria.
Förderung
- Medical University of Vienna
Zitieren
APA
Chiari, C., Schneider, E., Stamm, T., Peloschek, P., Kotz, R., & Windhager, R. (2024). Ultra-long-term results of the Chiari pelvic osteotomy in hip dysplasia patients: a minimum of thirty-five years follow-up. International Orthopaedics. https://doi.org/10.1007/s00264-023-05912-9
Vancouver
Chiari C, Schneider E, Stamm T, Peloschek P, Kotz R, Windhager R. Ultra-long-term results of the Chiari pelvic osteotomy in hip dysplasia patients: a minimum of thirty-five years follow-up. International Orthopaedics. 2024. doi:10.1007/s00264-023-05912-9
BibTeX
@article{Chiari2024,
author = {Chiari, Catharina and Schneider, Eleonora and Stamm, Tanja and Peloschek, Philipp and Kotz, Rainer and Windhager, Reinhard},
title = {Ultra-long-term results of the Chiari pelvic osteotomy in hip dysplasia patients: a minimum of thirty-five years follow-up},
journal = {International Orthopaedics},
year = {2024},
doi = {10.1007/s00264-023-05912-9}
}
EUVIMED